ArticleMethods in molecular biology (Clifton, N.J.)2025
Preparation of μSPOT Lactam-Cyclized Peptides for Ligand Optimization.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic peptides have emerged as promising therapeutic agents for targeting challenging protein-protein interactions (PPIs), combining high affinity, specificity, stability, and potential for improved drug-like properties. The outlined protocol describes a streamlined method for side chain-to-side chain lactam cyclization in a peptide array format based on the μSPOT method. The approach enables efficient synthesis and screening of cyclic peptide libraries with minimal synthetic effort, focusing on exploring cyclization positions and linker topology. The method is exemplified by developing cyclic peptide modulators of the APP/Mint2 PPI, a target implicated in Alzheimer's disease. The workflow integrates orthogonal protection strategies, analytical controls, and array-based binding assays, enabling the identification of binding-optimized cyclic peptides. Follow-up validation through fluorescence polarization assays demonstrated a strong correlation with array-based relative binding data (r
Indexed as
Identifiers
40663323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.